real-world-evidence
(39)
The $16.3 Billion Company Quietly Running Modern Medicine’s Back Office
IQVIA sits in the machinery between a molecule and a medicine cabinet - running trials, organizing health data and helping drugmakers decide what happens next. Now it is turning that unusually broad view of healthcare into an agentic AI platform.
Frekil
Frekil is an AI-powered real-world evidence (RWE) platform for life sciences that turns raw clinical data - EHR, claims, and registries - into regulatory-grade evidence in minutes instead of months. Its agentic pipeline runs the full study lifecycle, from literature review and cohort building through statistical analysis plan generation and final reports, while keeping clinical data isolated from AI models. Founded in 2025 by IIT Bombay alumni Nikhil Tiwari and Shivesh Gupta, Frekil is a Y Combinator (X25/P25) company serving pharma, biotech, CROs, and academic researchers.
Bruno Lempernesse
Bruno Lempernesse is the CEO of MDClone, an Israeli-founded healthcare data platform that lets organizations explore and share sensitive patient data using synthetic data that preserves privacy. A 25-year veteran of healthcare technology, data science, and life sciences, he joined MDClone as President of North America in September 2024 and stepped up to Chief Executive Officer in 2025. Before MDClone he was CEO of Carevive, a cancer-care and real-world-studies company acquired by Health Catalyst in 2024, and earlier spent two decades at Cegedim building its data and research business, plus leadership roles at SHYFT Analytics and Acorn AI (a Medidata company). He is an early pioneer of longitudinal patient data drawn from electronic medical records across Europe and the United States.
Briya
Briya is a healthcare data company that connects hospitals, health systems, and researchers to life sciences organizations through a secure, privacy-preserving data exchange network. Its blockchain-secured infrastructure standardizes electronic health records and keeps data at its source, while its flagship product, Briya AIRE, is a clinical-grade conversational AI research platform that lets scientists query and analyze real-world medical data in plain language. Founded in 2020 by David Lazerson and Guy Tish, Briya spans a global network of more than 120 million patient records and aims to accelerate medical and epidemiological research without the friction of traditional data integration.
Castor
Castor is a health-technology company that builds a cloud-based eClinical platform for running clinical trials - from electronic data capture (EDC) and eConsent to eCOA/ePRO and real-world evidence. Founded in 2012 in Amsterdam by physician-researcher Dr. Derk Arts, Castor set out to replace clunky, expensive trial software with a self-service, researcher-friendly system. Today it supports more than 15,000 studies across 90+ countries and is used by leading CROs and biopharma companies, while pushing decentralized trials and practical AI (Castor Catalyst, built with Google Cloud) into mainstream research.
Dandelion Health
Dandelion Health is a New York-based clinical AI and real-world data company that turns de-identified patient records from a network of U.S. hospitals into research-ready datasets and software for drug developers and AI teams. Its multimodal platform combines structured records, clinical notes, medical images, and raw biological signals such as ECG waveforms across roughly 15 million patients, helping pharmaceutical companies design smarter trials, discover biomarkers, generate real-world evidence, and validate healthcare algorithms against diverse populations.
Embleema
Embleema is a New York- and France-based healthcare technology company that builds a unified real-world data and evidence platform for clinical research. It aggregates clinical, genomic, and patient-reported data from electronic medical records, wearables, biospecimens, and patient apps into regulatory-grade datasets, and uses no-code protocol tools plus dynamic consent to help pharmaceutical sponsors, research sites, and patient groups run non-interventional and Phase IV studies faster and at lower cost. Founded in 2017 by Robert Chu, the company started with a patient-driven health blockchain and its analytics stack has been used by the FDA for genomic regulatory review.
H1
H1 is a New York-based healthcare data and technology company that maps the world's healthcare professionals, clinical trials and provider networks into a single platform. Founded in 2017 by Ariel Katz and Ian Sax, H1 aggregates billions of data points - peer-reviewed publications, clinical trial records, medical claims and provider directories - so pharmaceutical, biotech, medtech, health-plan and digital-health customers can find the right doctors, run better clinical trials, engage key opinion leaders and keep provider information accurate. Its stated mission is to create a healthier future by making healthcare information and evidence-based medicine accessible globally.
Derk Arts
Derk Arts is a Dutch physician-turned-entrepreneur and the founder and CEO of Castor, a clinical-trial software company he started in 2012 after coding the first version of its Electronic Data Capture platform himself. Trained as a medical doctor and epidemiologist with a PhD, he built Castor to make clinical research more inclusive, patient-centric, and data-driven. The platform now supports thousands of trials across roughly 90 countries and was used by the World Health Organization for its Solidarity Trial. Castor has raised more than $60 million, including a $45 million Series B in 2021, and Arts is a recognized voice on decentralized trials, eConsent, and the responsible use of AI in research.
Lyfegen
Lyfegen is a Swiss health-tech company that builds software to manage value-based drug pricing and rebate agreements. Its platform helps health insurers, governments, hospital payers, pharmaceutical firms and medical device makers automate complex rebate contracts, run pricing simulations and tap the world's largest library of value-based agreements - reducing administrative burden while helping patients access innovative therapies.
MDClone
MDClone is a healthcare data company that lets clinicians, researchers, and analysts explore patient data without touching real patient records. Its ADAMS platform ingests structured and unstructured health-system data into a longitudinal database, then generates statistically faithful synthetic data that carries no risk to patient privacy. That combination turns months-long, IRB-heavy data requests into self-service exploration, letting front-line staff ask their own questions, run analyses, and share results across organizations. Founded in Israel in 2016 and used across the U.S., Canada, and 100% of the Israeli healthcare market, MDClone has raised roughly $112M to expand data-driven discovery in health systems, government, payers, and life sciences.
Triomics
Triomics builds oncology-specific AI infrastructure that turns messy, unstructured cancer patient records into structured, cited, actionable data. Its OncoLLM engine and workflow agents automate clinical trial matching, visit preparation, and cancer registry reporting for leading cancer centers, cutting manual chart review time while increasing trial enrollment. Founded in 2021 and headquartered in New York, the company is used by 4 of the top 10 U.S. cancer hospitals and raised a $22M Series B led by Battery Ventures in May 2026.
Robert Chu
Robert Chu is the co-founder and CEO of Embleema, a New York-based clinical research platform that collects and generates regulatory-grade evidence to accelerate precision medicine. He founded the company in 2017 after nearly three decades in enterprise technology and life sciences data, including roles as Senior Vice President of Global Technology Solutions at IQVIA (formerly QuintilesIMS), where he ran a 1,400-person, $800M SaaS business, and prior leadership positions at IMS Health in France, China, and Asia Pacific, following 15+ years at IBM. Trained as an engineer at Ecole Polytechnique in Paris, he now works at the intersection of patient consent, blockchain, and clinical data collection, with Embleema partnering with pharma sponsors and the FDA on real-world evidence workflows.
Century Health
Century Health is a New York-based health technology company that turns fragmented, messy electronic health record data into clean, structured, analysis-ready real-world evidence. Its AI-powered platform, CHARM (Century Health Abstraction & Retrieval Model), automates the curation, abstraction, and de-identification of clinical data to build disease-specific patient registries for pharmaceutical and life sciences research. Founded in 2023 by Vish Srivastava and Sanjay Hariharan, the company reports 97% accuracy against clinical expert judgment and raised a $5M seed round in 2026 led by Origin Ventures.
Constant Therapy
Constant Therapy is a Boston-area digital health company that turns speech, language, and cognitive rehabilitation into an AI-personalized app. Spun out of Boston University's Aphasia Research Laboratory in 2012, its platform delivers more than 100,000 evidence-based exercises across 80-plus task categories to people recovering from stroke, traumatic brain injury, aphasia, dementia, and other neurological conditions - and to the clinicians who treat them. A patented NeuroPerformance Engine adapts each session to the individual, extending therapy beyond the clinic and into daily home practice.
People Science
People Science is a Los Angeles clinical research organization that turns rigorous clinical trials into software. Its platform, Chloe, lets wellness and health brands design, launch, and run decentralized, IRB-approved studies entirely from participants' homes - integrating wearables, lab partners, and remote data collection so that supplements, nutraceuticals, cannabinoids, psychedelics, and food-as-medicine products can earn real clinical evidence at a fraction of the cost and time of a traditional CRO. Founded by MD-PhD co-CEOs Belinda Tan and Noah Craft, who previously built Science 37 into a billion-dollar clinical trials company, People Science aims to bring evidence to an industry long defined by claims.
Medeloop
Medeloop is an AI-powered clinical research platform building an operating system for medical evidence - from grant discovery to real-world evidence generation to point-of-care intelligence. Founded by former surgeon Dr. Rene Caissie, the San Francisco company uses agentic AI to automate biostatistics, study monitoring, and protocol compliance for academic medical centers, health systems, and pharma.
Belinda Tan
Belinda Tan is a physician-scientist turned serial founder who builds the missing evidence layer for wellness. An MIT-trained, UCLA MD/PhD dermatopathologist, she co-founded Science 37 to pioneer decentralized, telemedicine-enabled clinical trials, then launched People Science, a Los Angeles public-benefit company she co-leads with her husband Noah Craft. Her mission: bring the rigor of the randomized trial to the things people already use - probiotics, traditional Chinese medicine, food-as-medicine, psychedelics - so wellness can be backed by data instead of marketing.
Vish Srivastava
Vish Srivastava is the co-founder and CEO of Century Health, a New York based AI company turning the messy, unstructured clinical notes buried inside electronic health records into structured, analyzable real-world evidence. Century's abstraction engine, CHARM, reads doctors' notes and pathology reports and pulls out clinical variables with 97% validated accuracy while keeping traceability back to the source document. The company focuses on therapeutic areas like gastroenterology, neurology, and rheumatology, and raised an oversubscribed $5M seed round in May 2026 led by Origin Ventures. Srivastava's pitch is simple and stubborn: the data needed to accelerate medical breakthroughs has already been collected during patient care; it just needs to be made accessible and actionable.
Verantos
Verantos is a Menlo Park healthcare technology company that turns messy, fragmented patient records - including the clinical notes most platforms ignore - into research-grade real-world evidence (RWE) at scale. Using AI applied to the complete patient record and a rigorous focus on measured accuracy, completeness, and traceability, Verantos helps pharmaceutical companies, regulators, and health systems generate evidence that can hold up to FDA-grade scrutiny across every therapeutic area.
ClinChoice
ClinChoice is a mid-size, global, full-service contract research organization (CRO) that helps pharmaceutical, biotech, medical device, and consumer health companies run clinical trials and bring drugs and devices to market. Founded in 1995 and headquartered in Horsham, Pennsylvania, the firm employs roughly 4,000 people across the Americas, Europe, and Asia-Pacific, offering clinical development, biometrics, safety/pharmacovigilance, regulatory affairs, post-marketing real-world evidence, and technology services. After rebranding from Fountain Medical Development (FMD K&L) in 2020 and raising a $150M Series E in 2022, ClinChoice has grown through acquisitions to serve six of the top ten pharma companies while focusing on emerging and mid-size biotech innovators.
ConcertAI
ConcertAI is a Cambridge, Massachusetts company that combines real-world clinical, genomic, imaging, and claims data with applied AI to accelerate cancer research and clinical development. Through its CARA AI platform, large independent oncology data network, and Digital Trial Solutions, it helps biopharma companies, healthcare providers, and medical societies design smarter trials, match patients faster, and generate evidence on how treatments perform outside controlled studies.
HealthVerity
HealthVerity is a Philadelphia-based healthcare data technology company that runs what it calls the nation's largest privacy-protected healthcare and consumer data ecosystem. Through its Marketplace and a framework it brands IPGE (Identity, Privacy, Governance, Exchange), it lets pharmaceutical companies, payers, and government agencies discover, license, link, and synchronize de-identified data on more than 340 million U.S. individuals to build longitudinal patient journeys and generate real-world evidence - all in a HIPAA-compliant manner.
Andrew Kress
Andrew Kress is the co-founder and CEO of HealthVerity, the Philadelphia company that built one of the largest real-world healthcare data ecosystems and the technology to link, govern and exchange it without exposing patient identities. An English major from Yale who spent his career inside the plumbing of healthcare data - running SDI Health, then leading Healthcare Value Solutions at IMS Health - he started HealthVerity in 2014 to make fragmented, privacy-bound health data usable. The company raised $100M in Series D funding in 2021 led by Durable Capital Partners. Kress also serves on the boards of Philadelphia cultural institutions including the Pennsylvania Academy of the Fine Arts.
One Health Company (FidoCure)
One Health Company, known to vets and pet parents as FidoCure, brings human-grade precision oncology to dogs. It sequences canine tumors, pinpoints cancer-driving mutations, and uses an AI engine (Fetch) trained on the world's largest structured canine cancer dataset to recommend targeted, FDA-approved therapies. Because dog and human cancers share genetics, the company is also building a comparative-oncology data asset that could accelerate cancer drug development for both species.
Jeff Elton
Jeff Elton, Ph.D., is the founding CEO and now Vice Chairman of ConcertAI, a Cambridge-based company building generative and predictive AI on the world's largest multi-modal oncology dataset. He grew the company from a 2017 startup into a roughly $1.9 billion business with about 1,300 employees, acquiring TeraRecon's imaging technology and ASCO's CancerLinQ network along the way. A former Accenture managing director, Novartis research COO, and McKinsey partner, he co-authored the widely cited book Healthcare Disrupted and chairs the MassBio board.
xCures Inc.
xCures is an AI-powered health-data platform that automatically retrieves medical records from any care site in the United States, then structures, normalizes, and validates that messy, unstructured data into searchable, source-traceable clinical insights. Born in oncology, it generates regulatory-grade real-world evidence, AI-built clinical checklists, and natural-language patient summaries that help researchers, biopharma, advocacy groups, and clinicians understand each patient's full medical journey - and run continuously learning 'virtual trials' across all patients, all treatments, all the time.
PatientIQ
PatientIQ is a Chicago-based healthcare technology company that builds a cloud platform for systematically collecting, measuring, and analyzing patient-reported outcomes (PROs). Founded in 2016 by Matthew Gitelis, the company connects hospitals, health systems, private practices, and medical device makers on a single EHR-integrated system that turns outcomes data into actionable clinical and operational intelligence. PatientIQ has grown to serve more than 200 healthcare organizations and has collected outcomes data from over 1.4 million patients.
Curavit Clinical Research
Curavit Clinical Research is a Boston-based, all-virtual Contract Research Organization (CRO) that designs and runs decentralized clinical trials. Through its Virtual Clinical Site and STRATUS platform, Curavit recruits, enrolls, and monitors diverse patient populations remotely - eliminating physical site infrastructure and travel while improving data quality. The company specializes in trials for digital therapeutics (DTx) and partners with sponsors and existing CROs to fix the execution layer of clinical research, accelerating timelines and lowering costs.
Joel Morse
Joel Morse is the co-founder and CEO of Curavit Clinical Research, a virtual contract research organization (VCRO) that designs and runs decentralized clinical trials for digital therapeutics, devices and drugs. A mechanical engineer turned serial healthcare operator, he previously co-founded C3i Solutions in 1993 and built it into a global leader in tech-enabled clinical trial services before selling to Telerx in 2014. At Curavit he is betting that trials can be run where patients actually live, stitching together wearables, web recruitment and real-world evidence to reach people traditional sites never see.